‘Compelling’ new target found for monocytic AMLNovember 11, 2018Leukemia, Myelodysplasia, TransplantationAML
‘Encouraging’ phase 2 results in rel/ref AMLNovember 9, 2018Leukemia, Myelodysplasia, TransplantationAML
Quizartinib receives accelerated assessment for AMLNovember 7, 2018Leukemia, Myelodysplasia, TransplantationAML
Changes related to AML relapse may be reversibleNovember 6, 2018Leukemia, Myelodysplasia, TransplantationTransplantationAML
EVI1 overexpression promotes leukemogenesis, study suggestsNovember 1, 2018Leukemia, Myelodysplasia, TransplantationAML
Team finds potential therapeutic target for AMLOctober 31, 2018Leukemia, Myelodysplasia, TransplantationAML
MDM2 inhibitors could treat resistant AMLOctober 24, 2018Leukemia, Myelodysplasia, TransplantationAML
‘Intense’ end-of-life care may be common in HSCT recipientsOctober 19, 2018AnemiaLeukemia, Myelodysplasia, TransplantationTransplantationAMLALLMyelodysplastic Syndrome
Adoptive T-cell therapy treats PMLOctober 19, 2018CythemiasLeukemia, Myelodysplasia, TransplantationAML
Dataset could reveal better therapies for AMLOctober 18, 2018Leukemia, Myelodysplasia, TransplantationAML
FDA issues draft guidance on MRDOctober 16, 2018Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersMultiple MyelomaAMLALLCMLNon-Hodgkin Lymphoma
CDK8 inhibitor can fight AML, though it’s unclear howOctober 10, 2018Leukemia, Myelodysplasia, TransplantationAML
Novel agents changing treatment algorithm in AMLSeptember 25, 2018Leukemia, Myelodysplasia, TransplantationAML